198 related articles for article (PubMed ID: 31514860)
1. A biosensor for determination of the circulating biomarker CA125/MUC16 by Surface Plasmon Resonance Imaging.
Szymańska B; Lukaszewski Z; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Talanta; 2020 Jan; 206():120187. PubMed ID: 31514860
[TBL] [Abstract][Full Text] [Related]
2. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
[TBL] [Abstract][Full Text] [Related]
4. An amplified comparative fluorescence resonance energy transfer immunosensing of CA125 tumor marker and ovarian cancer cells using green and economic carbon dots for bio-applications in labeling, imaging and sensing.
Hamd-Ghadareh S; Salimi A; Fathi F; Bahrami S
Biosens Bioelectron; 2017 Oct; 96():308-316. PubMed ID: 28525848
[TBL] [Abstract][Full Text] [Related]
5. An immunosensor for the determination of carcinoembryonic antigen by Surface Plasmon Resonance imaging.
Szymanska B; Lukaszewski Z; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Anal Biochem; 2020 Nov; 609():113964. PubMed ID: 32979366
[TBL] [Abstract][Full Text] [Related]
6. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
8. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC).
Liu L; Xiang J; Chen R; Fu D; Hong D; Hao J; Li Y; Li J; Li S; Mou Y; Mai G; Ni Q; Peng L; Qin R; Qian H; Shao C; Sun B; Sun Y; Tao M; Tian B; Wang H; Wang J; Wang L; Wang W; Wang W; Zhang J; Zhao G; Zhou J; Yu X;
Int J Oncol; 2016 Mar; 48(3):900-7. PubMed ID: 26718269
[TBL] [Abstract][Full Text] [Related]
9. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
11. Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, β-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance (SPR) analysis.
Pal MK; Rashid M; Bisht M
Biosens Bioelectron; 2015 Nov; 73():146-152. PubMed ID: 26057734
[TBL] [Abstract][Full Text] [Related]
12. Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia.
Winarto H; Laihad BJ; Nuranna L
Asian Pac J Cancer Prev; 2014; 15(5):1949-53. PubMed ID: 24716917
[TBL] [Abstract][Full Text] [Related]
13. Developing a mass spectrometry-based assay for the ovarian cancer biomarker CA125 (MUC16) using suspension trapping (STrap).
Schuster-Little N; Madera S; Whelan R
Anal Bioanal Chem; 2020 Sep; 412(24):6361-6370. PubMed ID: 32215689
[TBL] [Abstract][Full Text] [Related]
14. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
[TBL] [Abstract][Full Text] [Related]
15. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
16. Detection of serum human epididymis secretory protein 4 in patients with ovarian cancer using a label-free biosensor based on localized surface plasmon resonance.
Yuan J; Duan R; Yang H; Luo X; Xi M
Int J Nanomedicine; 2012; 7():2921-8. PubMed ID: 22745553
[TBL] [Abstract][Full Text] [Related]
17. A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological-Oncological Diseases.
Szymanska B; Lukaszewski Z; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Biosensors (Basel); 2023 Feb; 13(2):. PubMed ID: 36832045
[TBL] [Abstract][Full Text] [Related]
18. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
[TBL] [Abstract][Full Text] [Related]
19. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]